AbbVie to buy Allergan in $63B cash and stock deal

AbbVie buying Allergan in $63B deal for its post-Humira future

That's below the total consideration of $188.24 per share in AbbVie's cash-and-stock offer, perhaps reflecting some concern over the deal's ...

AbbVie Strikes Deal to Acquire Allergan for About $63 Billion - WSJ

The takeover is worth about $188 a share in cash and stock, the companies said. The price represents a 45% premium over Allergan's closing share ...

AbbVie to buy Allergan in $63B cash and stock deal

AbbVie plans to acquire Allergan in a cash and stock deal valued at $63 billion, one of the biggest mergers in the healthcare industry this ...

Humira maker AbbVie to acquire Botox maker Allergan for $63 billion

The deal calls for North Chicago, Illinois-based AbbVie to pay cash and stock worth about $63 billion for Dublin-based Allergan.

AbbVie to Acquire Allergan for $63B - Big Molecule Watch -

U.S.-based AbbVie, Inc. has reached a deal to acquire Irish pharmaceutical company Allergan PLC for about $63 billion, according to an ...

Analysts rip into AbbVie, Allergan's $63B deal, citing culture clash ...

AbbVie made a major splash Tuesday with its proposed $63 billion buyout of Allergan that'll create a top-5 pharma giant. But analysts and investors were hardly ...

AbbVie to buy Allergan for $63B - Fox Business

The pharmaceutical company will be acquired in a cash and stock deal, with the transaction equity value based on AbbVie's closing stock price of ...

Botox Maker Allergan Sold to AbbVie for $63B | CFO.com

... buy Allergan, the maker of Botox, in a cash and stock transaction. Under the terms of the deal, Allergan shareholders would receive 0.8660 AbbVie shares and ...

AbbVie makes $63B bid for Botox maker Allergan

FILE - This Jan. 24, 2015, file photo, shows the exterior of AbbVie, in Lake Bluff, Ill. AbbVie is buying Botox maker Allergan in a cash-and-stock deal the ...

AbbVie makes $63B bid for Botox maker Allergan - Medical Xpress

AbbVie will pay $120.30 in cash and a portion of AbbVie stock for each Allergan share. That amounts to $188.24 per share, or a 45% premium to ...

AbbVie gains U.S. nod for $63B Allergan takeover - MassDevice

Pharmaceutical giant AbbVie (NYSE:ABBV) has won US antitrust approval for its purchase of Allergan (NYSE:AGN) for $63 billion in cash and stock.

AbbVie Makes $63B Bid for Botox Maker Allergan - NBC Bay Area

AbbVie is buying Botox maker Allergan in a cash-and-stock deal valued at about $63 billion. The maker of the blockbuster immune disorder ...

Illinois-based drugmaker AbbVie to buy rival - North

North Chicago-based drugmaker AbbVie is buying Botox-maker Allergan for $63 billion in cash and stock — a deal designed to reduce AbbVie's reliance on its ...

AbbVie makes $63B bid for Botox maker Allergan - Times Union

The deal follows a familiar formula: Snap up a smaller drugmaker to boost revenue and cut jobs and other costs in the short term, while ...

AbbVie Agrees to Acquire Allergan with $63B Deal - Pharmacy Times

Announced by both companies today, the new combined company will consist of franchises across immunology, hematologic oncology, medical ...

Cravath Defectors at Kirkland Advise AbbVie on $63B Deal With ...

The AbbVie-Allergan cash-and-stock deal, which is expected to close in early 2020, values Allergan at about $188 a share, which is a 45 ...

AbbVie gains U.S. nod for $63B Allergan takeover

Pharmaceutical giant AbbVie (NYSE:ABBV) has won US antitrust approval for its purchase of Allergan (NYSE:AGN) for $63 billion in cash and stock.

AbbVie to buy Allergan in $63b mega-merger - PharmaTimes

The two pharma giants have entered into a definitive transaction agreement worth approximately $63 billion, based on the closing price of AbbVie's common stock ...

Kirkland, Wachtell Advise On AbbVie's $63B Merger With Allergan

Kirkland & Ellis advised AbbVie Inc. in its $63 billion cash and stock purchase of Botox-maker Allergan Inc., which was represented by Wachtell.

AbbVie to acquire Allergan in $63B deal - Drug Store News

AbbVie and Allergan announced today that the companies have entered into a definitive transaction agreement under which AbbVie will acquire ...